Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson’s disease treatment

Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson’s disease treatment
Acta Pharm Sin B. 2021 May;11(5):1213-1226. doi: 10.1016/j.apsb.2021.01.009. Epub 2021 Jan 26.ABSTRACTThe gut microbiota plays an important role in regulating the pharmacokinetics and pharmacodynamics of many drugs. FLZ, a novel squamosamide derivative, has been shown to have neuroprotective effects on experimental Parkinson's disease (PD) models. FLZ is under phase Ⅰ clinical trial now, while the underlying mechanisms contributing to the ... read more
Source: PubMedPublished on 2021-06-07By Junmei Shang